Pharmacotherapeutic efficiency and advantages of the combined treatment of patients with type 2 diabetes mellitus

V.I. Pankiv

Abstract


Background. The early prescription of a combination of extended-release metformin with glimepiride influencing different links of the pathogenesis of type 2 diabetes mellitus (DM) is grounded in the article. The purpose of the research was to evaluate the dynamics of glycated haemoglobin (HbA1c) after the period of supervision as compared to the baseline, and also to determine additional parameters of efficiency, safety, and tolerability of Duglimax manufactured by Кusum Pharm (Ukraine) in the therapy of type 2 DM. Materials and methods. The study included 46 patients with type 2 DM divided into two groups. For the patients of the first group (n = 26), who previously received metformin preparations at a dose of up to 2000 mg/day, the combined preparation Duglimax (metformin 500 mg and glimepiride 2 mg) was prescribed, and also extended-release metformin (Metamin SR) in the evening. The patients of the second group (n = 20) continued the reception of extended-release metformin twice daily in a dose of 2000–2500 mg/day. Results. After 12 weeks of therapy, in patients of the first group, the level of НbА1с significantly decreased to 6.72 ± 0.29 %. The level of insulin in the first group was 14.06 ± 1.81 mIU/ml after treatment (in baseline level of 19.17 ± 2.05 mIU/ml), HOMA-IR — 3.14 ± 0.21 (vs initial one of 5.92 ± 1.46). Results of the clinical study show the absence of hypoglycemia development in patients receiving Duglimax during the follow-up period. Conclusions. Combined antidiabetic therapy with Duglimax for 12 weeks results in the substantial decrease of HbA1c level and achievement of target indexes of carbohydrate metabolism in type 2 DM patients. The good tolerability and high safety of Duglimax were registered during the period of supervision.


Keywords


type 2 diabetes mellitus; treatment; metformin; glimepiride

References


Mackawy AMH, Al-ayed BM, Al-rashidi BM. Vitamin D deficiency and its association with thyroid disease. Int J Health Sci (Qassim). 2013;7(3):267-75. PMCIS:PMC3921055.

Toulis K, Tsekmekidou X, Potolidis E, et al. Thyroid autoimmunity in the context of type 2 diabetes mellitus: implications for vitamin D. Int J Endocnol. 2015;710363. doi: 10.1155/2015/710363.

Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10(3):185-97. doi: 10.1111/j.1463-1326.2007.00710.x.

Wang J, Li S, Chen G, et al. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients. 2015;7:2485-98. doi: 10.3390/nu7042485.

Al-Shoumer KAS, Al-Essa TM. Is there a relationship between vitamin D with insulin resistance and diabetes mellitus. World J Diabetes. 2015;6(8):1057-64. doi: 10.4239/wjd.v6.i8.1057.

Maestro B, Molero S, Bajo S, Dávila N, Calle C. Transcriptional activation of the human insulin receptor gene by 1, 25-dihydroxyvitamin D(3). Cell Biochem Funct. 2002;20(3):227-32. doi: 10.1002/cbf.951.

Díez JJ, Iglesias P. An analysis of the relative risk for hypothyroidism in patients with Type2 diabetes.Diabet Med. 2012;29(12):1510-4. doi: 10.1111/j.1464-5491.2012.03687.x.

Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin Endocrinol (Oxf). 2011 Jul;75(1):1-9. doi: 10.1111/j.1365-2265.2011.04029.x.

Tanabe N, Saito K, Yamada Y, Takasawa T, Seki N, Suzuki H. Risk assessment by post-challenge plasma glucose, insulin response ratio, and other indices of insulin resistance and/or secretion for predicting the development of type 2 diabetes. Inter Med. 2009;48:401-9. doi: 10.2169/internalmedicine.48.1325.

von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr. 2010 Feb;103(4):549-55. doi: 10.1017/S0007114509992017.

Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non-diabetic adults. Diabetes Care. 2007;30(4):980-6. doi: 10.2337/dc06-1994.

Witham MD, Dore FJ, Druburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2010;53(10):2112-9. doi: 10.1007/s00125-010-1838-1.

Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabetic Medicine. 2009;26(1):19-27. doi: 10.1111/j.1464-5491.2008.02636.x.

Bland R, Markovic D, Hills CE, et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89-90(1-5):121-5. doi: 10.1016/j.jsbmb.2004.03.115.




DOI: https://doi.org/10.22141/2224-0721.13.6.2017.112887

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru